TY - CHAP M1 - Book, Section TI - Antifungal Agents A1 - Metjian, Talene A. A1 - Fisher, Brian A2 - Shah, Samir S. A2 - Kemper, Alex R. A2 - Ratner, Adam J. PY - 2019 T2 - Pediatric Infectious Diseases: Essentials for Practice, 2e AB - The population of immunocompromised children at risk for invasive fungal disease continues to grow. This population includes children with primary and acquired immune deficiencies, recipients of solid-organ and stem cell transplants, children with malignancy receiving chemotherapy agents, and those with autoinflammatory or autoimmune conditions receiving immune-modulating therapies. Fortunately, in conjunction with this growth, there has been a steady growth in the armamentarium of antifungal agents, including development of new classes of antifungal agents (e.g., echinocandins), as well as newer generations of an older antifungal class, the azoles. Despite the increase in number of antifungal agents, the fungal pathogens encountered in children are variable and often responsive to only a select number of antifungal agents. Coupled with the risk of significant drug–drug interactions, therapeutic options available to a clinician for a given clinical scenario are limited. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspediatrics.mhmedical.com/content.aspx?aid=1157319694 ER -